NASDAQ:EDIT 2 November 2025

CRISPR Therapeutics stock slides after CFO share-sale filing; JPM conference next

CRISPR Therapeutics shares fell 4.3% to $54.00 after a filing showed CFO Raju Prasad exercised and sold 29,700 shares under a preset trading plan. The move comes ahead of the company’s Jan. 12 slot at the J.P. Morgan Healthcare Conference and an expected mid-February earnings report. Gene-editing peers also traded lower. CASGEVY revenue and rollout remain key investor focus.

9 January 2026

Biotechnology·NASDAQ:BEAM·NASDAQ:CRSP·NASDAQ:EDIT·NASDAQ:NTLA·NASDAQ:VRTX·Pharmaceuticals·Stock Market

CRISPR Therapeutics stock (CRSP) slips into 2026 as New Year’s Day shuts Wall Street — what investors watch next

CRISPR Therapeutics shares closed down 1.4% at $52.44 on Dec. 31, the final trading day of 2025. U.S. markets were shut Jan. 1 for New Year’s. Investors are watching for early-2026 updates on Casgevy’s rollout and the next earnings schedule as trading resumes Jan. 2. Biotech ETFs were little changed in light year-end trading.

2 January 2026

Biotechnology·NASDAQ:BEAM·NASDAQ:CRSP·NASDAQ:EDIT·NASDAQ:NTLA·NASDAQ:VRTX·Stock Market

Premarket Shock: Why CRISPR Therapeutics Could Move Big Today

The FDA will announce a new fast-track approval process for personalized gene-editing therapies in early November, sending CRISPR Therapeutics shares up 8% and Editas up 12%. CRSP reported over 90% mRNA correction in preclinical CTX460 data and will present Phase 1 CTX310 results at the AHA conference Nov. 8. Intellia paused a TTR amyloidosis trial after a liver injury, causing its stock to fall 46%.

2 November 2025

Biotechnology·LSE:AZN·NASDAQ:BEAM·NASDAQ:CRSP·NASDAQ:EDIT·NASDAQ:NTLA·Stock Market

Duke Energy Shares Appear Overvalued Despite Recent Gains, Dividend Model Shows
April 3, 2026, 1:48 AM EDT. Duke Energy's (DUK) stock closed at $132.22, up 2.2% over the past week and 10.4% over one year. However, a Dividend Discount Model (DDM) analysis suggests the shares are overvalued by nearly 70% compared to an intrinsic value estimate of $77.82. The model focuses on projected dividend income, noting Duke's high payout ratio of 88.47% and modest dividend growth rate of 1.02%. While the stock has shown solid returns over longer periods, its recent price surge raises questions about whether market sentiment outpaces fundamentals. Investors balancing income stability against pricing power in the utilities sector should consider this discrepancy when evaluating Duke Energy's valuation and risk profile.